インフルエンザ診断市場

出版：MarketsandMarkets

Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS)), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026

–

–

インフルエンザ診断市場 製品（テストキット、機器）、テストタイプ（従来型（RIDT、ウイルス培養、血清学的）、分子（PCR、INAAT-NASBAT、TMABAS））、エンドユーザー（診断研究所、病院、クリニック）、地域別

The global influenza diagnostics market is projected to reach USD 1.1 billion by 2026 from USD 0.8billion in 2021, at a CAGR of 7.7% during the forecast period. Market growth is driven by factors such as the growth in influenza research for diagnostic technologies,rising demand for rapid disease diagnosis and increasing prevalence of influenza. On the other hand, therising healthcare costs, variabilities in test sensitivity and specificityare the major factors hampering the growth of this market.
“The test kits and reagents segment accounted for the highest growth rate in theinfluenza diagnostics market, by product, during the forecast period”
Theinfluenza diagnostics market is segmented into test kits and reagents, instruments and other productsbased on product. In 2020, the test kits and reagents segment accounted for the highest growth rate in the influenza diagnostics market. Increasing prevalence of influenza and rising demand for rapid disease diagnosis are major factor contributing to the growth of this segment.
“The molecular diagnostic tests segment accounted for the highest growth rate in the influenza diagnostics market, by test type, during the forecast period”
The influenza diagnostics market is segmented into molecular diagnostic tests and traditional diagnostic tests based on test type. In 2020, the molecular diagnostic tests segment accounted for the highest growth rate in the influenza diagnostics market. Growth in influenza research for diagnostic technologies and rising demand for rapid disease diagnosis are major factor contributing to the growth of this segment.
“Diagnostic laboratories segment accounted for the highest CAGR”
Based onend user, the influenza diagnosticsmarket is segmented intodiagnostic laboratories, hospitals and clinics and other end users. In 2020, the hospitals and clinics segment accounted for the highest CAGR. This can be attributed to therising demand for rapid disease diagnosis and increasing prevalence of influenza.
“Asia Pacific: The fastest-growing regionin influenza diagnostics market”
The global influenza diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period.Factors such as the rising demand for rapid disease diagnosis and growth in influenza research for diagnostic technologiesare driving the growth of the influenza diagnostics market in this region.

The primary interviews conducted for this report can be categorized as follows:

•By Company Type: Tier 1 – 40%, Tier 2 – 30%,and Tier 3 -30%
•By Designation: C-level – 27%, D-level – 18%, and Others – 55%
•By Region: North America -51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

•Danaher Corporation (US)
•Siemens Healthineers (Germany)
•Thermo Fisher Scientific, Inc. (US)
•F. Hoffmann-LA Roche AG (Switzerland)
•Abbott Laboratories, Inc. (Us)
•Hologic, Inc. (US)
•bioMérieux SA (France)
•Quidel Corporation (US)
•Becton, Dickinson and Company (US)
•Meridian Bioscience (US)
•GenMark Diagnostics, Inc. (US)
•Luminex Corporation (US)
•Tecan Trading AG (Switzerland)
•DiaSorin SA (Italy)
•altona Diagnostics GmbH (Germany)
•SEKISUI Diagnostics (US)
•SA Scientific Ltd. (US)
•CorisBioConcept SPRL (Belgium)
•ELITech Group (France)
•Mast Group Ltd. (UK)
•Genome Diagnostics, Pvt. Ltd. (India)
•Germaine Laboratories, Inc. (US)
•Response Biomedical Corp. (Canada)
•Tauns Laboratories, Inc. (Japan)
•3B BlackBio Biotech India Ltd. (India)
Research Coverage:
This report provides a detailed picture of the global influenza diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product, test type, end userand region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall influenza diagnostics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

目次

1INTRODUCTION28
1.1OBJECTIVES OF THE STUDY28
1.2MARKET DEFINITION28
1.2.1INCLUSIONS & EXCLUSIONS OF THE STUDY29
1.2.2MARKETS COVERED30
FIGURE 1INFLUENZA DIAGNOSTICS MARKET SEGMENTATION30
1.2.3YEARS CONSIDERED FOR THE STUDY31
1.3CURRENCY31
1.4LIMITATIONS31
1.5STAKEHOLDERS32
1.6SUMMARY OF CHANGES32
2RESEARCH METHODOLOGY34
2.1RESEARCH DATA34
2.2RESEARCH APPROACH34
FIGURE 2INFLUENZA DIAGNOSTICS MARKET: RESEARCH DESIGN34
2.2.1SECONDARY DATA35
2.2.1.1Key data from secondary sources35
2.2.2PRIMARY DATA36
2.2.2.1Key data from primary sources36
2.2.2.2Key industry insights37
FIGURE 3BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION38
2.3MARKET SIZE ESTIMATION38
2.3.1BOTTOM-UP APPROACH39
FIGURE 4INFLUENZA DIAGNOSTICS MARKET: BOTTOM-UP APPROACH39
FIGURE 5CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS39
2.3.2TOP-DOWN APPROACH40
FIGURE 6INFLUENZA DIAGNOSTICS MARKET: TOP-DOWN APPROACH40
2.4MARKET BREAKDOWN & DATA TRIANGULATION40
FIGURE 7DATA TRIANGULATION METHODOLOGY41
2.5ASSUMPTIONS FOR THE STUDY42
2.6GROWTH RATE ASSUMPTIONS42
2.7LIMITATIONS43
2.8RISK ASSESSMENT43
2.9COVID-19 HEALTH ASSESSMENT43
2.10COVID-19 ECONOMIC ASSESSMENT44
 
2.11ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO44
FIGURE 8CRITERIA IMPACTING THE GLOBAL ECONOMY44
FIGURE 9RECOVERY SCENARIO OF THE GLOBAL ECONOMY45
2.12ASSESSMENT OF THE IMPACT OF COVID-19 ON THE INFLUENZA DIAGNOSTICS MARKET46
3EXECUTIVE SUMMARY47
FIGURE 10INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION)47
FIGURE 11INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2021 VS. 2026 (USD MILLION)48
FIGURE 12INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION)48
FIGURE 13INFLUENZA DIAGNOSTICS MARKET, BY REGION,
2021 VS. 2026 (USD MILLION)49
4PREMIUM INSIGHTS50
4.1INFLUENZA DIAGNOSTICS MARKET OVERVIEW50
FIGURE 14INCREASING PREVALENCE OF INFLUENZA TO DRIVE MARKET GROWTH50
4.2INFLUENZA DIAGNOSTICS MARKET SHARE, BY PRODUCT, 2021 VS. 202650
FIGURE 15TEST KITS & REAGENTS WILL CONTINUE TO DOMINATE THE MARKET IN 202650
4.3INFLUENZA DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2021 VS. 202651
FIGURE 16MOLECULAR DIAGNOSTIC TESTS TO DOMINATE THE MARKET DURING THE FORECAST PERIOD51
4.4INFLUENZA DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 202651
FIGURE 17DIAGNOSTIC LABORATORIES ARE THE LARGEST END USERS OF THE INFLUENZA DIAGNOSTICS MARKET51
4.5INFLUENZA DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES52
FIGURE 18NORTH AMERICA TO COMMAND THE LARGEST SHARE AND ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE INFLUENZA DIAGNOSTICS MARKET DURING THE FORECAST PERIOD52
5MARKET OVERVIEW53
5.1INTRODUCTION53
5.2MARKET DYNAMICS53
FIGURE 19INFLUENZA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES53
5.2.1DRIVERS53
5.2.1.1Increasing prevalence of influenza53
5.2.1.2Growth in influenza research for diagnostic technologies54
5.2.1.3Rising demand for rapid disease diagnosis54
5.2.2RESTRAINTS55
5.2.2.1Variabilities in test sensitivity and specificity55
5.2.2.2Rising healthcare costs55
5.2.3OPPORTUNITIES55
5.2.3.1Advancements in genomic and proteomic technologies55
5.2.3.2Significant growth prospects in developing countries55
5.2.4CHALLENGES56
5.2.4.1Lack of skilled professionals56
5.2.4.2Stringent regulatory frameworks56
5.3IMPACT OF COVID-19 ON THE INFLUENZA DIAGNOSTICS MARKET57
5.4PRICING ANALYSIS58
TABLE 1PRICES OF INFLUENZA DIAGNOSTIC PRODUCTS (2021)58
5.5PATENT ANALYSIS59
5.6TRADE ANALYSIS59
5.6.1TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS59
TABLE 2IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)59
TABLE 3EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS,
BY COUNTRY, 2016–2020 (USD MILLION)60
5.7VALUE CHAIN ANALYSIS60
FIGURE 20MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASES60
5.8SUPPLY CHAIN ANALYSIS61
FIGURE 21DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES62
5.9ECOSYSTEM ANALYSIS OF THE INFLUENZA DIAGNOSTICS MARKET62
FIGURE 22INFLUENZA DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS62
5.9.1ROLE IN THE ECOSYSTEM62
5.10PORTER’S FIVE FORCES ANALYSIS63
TABLE 4INFLUENZA DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS63
5.10.1THREAT FROM NEW ENTRANTS64
5.10.2THREAT FROM SUBSTITUTES64
5.10.3BARGAINING POWER OF BUYERS64
5.10.4BARGAINING POWER OF SUPPLIERS64
5.10.5DEGREE OF COMPETITION64
5.11PESTLE ANALYSIS65
5.12REGULATORY LANDSCAPE66
5.12.1NORTH AMERICA66
5.12.1.1US66
5.12.1.2Canada66
5.12.2EUROPE66
5.12.3ASIA PACIFIC66
5.12.3.1Japan66
5.12.3.2India67
5.12.3.3China67
5.12.4LATIN AMERICA67
5.12.4.1Brazil67
5.12.4.2Mexico67
5.12.5MIDDLE EAST67
5.12.6AFRICA68
5.13TECHNOLOGY ANALYSIS68
5.14DISRUPTIVE TECHNOLOGIES IN THE INFLUENZA DIAGNOSTICS MARKET69
5.14.1REVENUE SHIFT & REVENUE POCKETS FOR THE INFLUENZA DIAGNOSTICS MARKET69
FIGURE 23REVENUE SHIFT FOR THE INFLUENZA DIAGNOSTICS MARKET69
6INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT70
6.1INTRODUCTION71
TABLE 5INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)71
6.2TEST KITS & REAGENTS71
6.2.1REPEAT PURCHASE OF TEST KITS & REAGENTS TO DRIVE MARKET GROWTH IN THE COMING YEARS71
FIGURE 24INSIGHTS FROM INDUSTRY EXPERTS ON TEST KITS & REAGENTS72
TABLE 6INFLUENZA DIAGNOSTICS MARKET FOR TEST KITS & REAGENTS, BY REGION, 2019–2026 (USD MILLION)72
6.3INSTRUMENTS73
6.3.1INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO PROPEL MARKET GROWTH73
TABLE 7KEY INSTRUMENTS IN THE INFLUENZA DIAGNOSTICS MARKET74
TABLE 8INFLUENZA DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2019–2026 (USD MILLION)74
6.4OTHER PRODUCTS74
TABLE 9INFLUENZA DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2019–2026 (USD MILLION)75
7INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE76
7.1INTRODUCTION77
TABLE 10INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)77
7.2MOLECULAR DIAGNOSTIC TESTS77
TABLE 11MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)78
TABLE 12MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION,
2019–2026 (USD MILLION)78
7.2.1POLYMERASE CHAIN REACTION TESTS78
7.2.1.1Ability of PCR tests to distinguish between influenza A and B viruses is driving its adoption in clinical settings78
TABLE 13POLYMERASE CHAIN REACTION TESTS MARKET, BY REGION,
2019–2026 (USD MILLION)79
7.2.2ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS79
TABLE 14ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)80
TABLE 15ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)80
7.2.2.1Transcription-mediated amplification-based assays80
7.2.2.1.1Wide application range in pathogen detection to drive the market growth80
TABLE 16TRANSCRIPTION-MEDIATED AMPLIFICATION-BASED ASSAYS MARKET,
BY REGION, 2019–2026 (USD MILLION)81
7.2.2.2Loop-mediated isothermal amplification-based assays81
7.2.2.2.1Rapidity, stability, and sensitivity have driven the use of loop-mediated isothermal amplification-based assays81
TABLE 17LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS MARKET,
BY REGION, 2019–2026 (USD MILLION)81
7.2.2.3Nucleic acid sequence-based amplification assays82
7.2.2.3.1Nucleic acid sequence-based amplification assays are preferred in hospitals and clinical settings as they reduce the need for additional reverse transcription steps82
TABLE 18NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION ASSAYS MARKET,
BY REGION, 2019–2026 (USD MILLION)82
7.2.2.4Other isothermal nucleic acid amplification tests82
TABLE 19OTHER ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY REGION, 2019–2026 (USD MILLION)83
7.2.3OTHER MOLECULAR DIAGNOSTIC TESTS83
TABLE 20OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION,
2019–2026 (USD MILLION)83
7.3TRADITIONAL DIAGNOSTIC TESTS84
TABLE 21TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)84
TABLE 22TRADITIONAL DIAGNOSTIC TESTS MARKET, BY REGION,
2019–2026 (USD MILLION)84
7.3.1RAPID INFLUENZA DIAGNOSTIC TESTS84
7.3.1.1Rapid influenza diagnostic tests are widely used due to their ease of use and rapid interpretability of results84
TABLE 23RAPID INFLUENZA DIAGNOSTIC TESTS MARKET, BY REGION,
2019–2026 (USD MILLION)85
7.3.2VIRAL CULTURE TESTS85
7.3.2.1Wide use of viral cultures as confirmatory tests to ensure the results of RIDTs to drive market growth85
TABLE 24VIRAL CULTURE TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)86
7.3.3DIRECT FLUORESCENT ANTIBODY TESTS86
7.3.3.1Adoption of DFA tests is increasing due to their higher sensitivity compared to RIDTs86
TABLE 25DIRECT FLUORESCENT ANTIBODY TESTS MARKET, BY REGION,
2019–2026 (USD MILLION)87
7.3.4SEROLOGICAL TESTS87
7.3.4.1Development of lab-on-chip-based multiplex assays to support market growth87
TABLE 26SEROLOGICAL TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)88
 
8INFLUENZA DIAGNOSTICS MARKET, BY END USER89
8.1INTRODUCTION90
TABLE 27INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)90
8.2DIAGNOSTIC LABORATORIES90
8.2.1LARGE NUMBER OF INFLUENZA DIAGNOSTIC TESTS PERFORMED IN DIAGNOSTIC LABORATORIES TO DRIVE MARKET GROWTH90
TABLE 28INFLUENZA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2019–2026 (USD MILLION)91
8.3HOSPITALS & CLINICS91
8.3.1GROWING GLOBAL NUMBER OF HOSPITALS DUE TO INCREASING INFECTIOUS DISEASE INCIDENCE TO DRIVE MARKET GROWTH91
TABLE 29INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY REGION, 2019–2026 (USD MILLION)92
8.4OTHER END USERS92
TABLE 30INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)92
9INFLUENZA DIAGNOSTICS MARKET, BY REGION93
9.1INTRODUCTION94
TABLE 31INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)94
TABLE 32INFLUENZA DIAGNOSTICS MARKET, BY REGION,
2019–2026 (MILLION TESTS)94
9.2NORTH AMERICA95
FIGURE 25NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT95
TABLE 33NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)96
TABLE 34NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)96
TABLE 35NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)96
TABLE 36NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)97
TABLE 37NORTH AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)97
TABLE 38NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)97
TABLE 39NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)98
9.2.1US98
9.2.1.1Technological advancements in influenza diagnostics to favor market growth in the US98
TABLE 40US: PRODUCT APPROVALS IN THE INFLUENZA DIAGNOSTICS MARKET98
TABLE 41US: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)99
TABLE 42US: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)99
TABLE 43US: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)100
TABLE 44US: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)100
TABLE 45US: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)100
TABLE 46US: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)101
9.2.2CANADA101
9.2.2.1Government initiatives for developing diagnostic techniques to support market growth in Canada101
TABLE 47CANADA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)102
TABLE 48CANADA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)102
TABLE 49CANADA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)102
TABLE 50CANADA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION)103
TABLE 51CANADA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)103
TABLE 52CANADA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)103
9.3EUROPE104
TABLE 53EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)104
TABLE 54EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)105
TABLE 55EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)105
TABLE 56EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)105
TABLE 57EUROPE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION)106
TABLE 58EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)106
TABLE 59EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)106
9.3.1GERMANY107
9.3.1.1Increasing demand for technologically advanced diagnostic techniques to drive market growth in Germany107
TABLE 60GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)107
TABLE 61GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)107
TABLE 62GERMANY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)108
TABLE 63GERMANY: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION)108
TABLE 64GERMANY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)108
TABLE 65GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)109
9.3.2ITALY109
9.3.2.1Well-developed healthcare system in Italy to drive the adoption of advanced diagnostic technologies109
TABLE 66ITALY: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)109
TABLE 67ITALY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)110
TABLE 68ITALY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)110
TABLE 69ITALY: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)110
TABLE 70ITALY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)111
TABLE 71ITALY: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)111
9.3.3FRANCE111
9.3.3.1High healthcare expenditure by the government to drive market growth in France111
TABLE 72FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)112
TABLE 73FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)112
TABLE 74FRANCE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)112
TABLE 75FRANCE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION)113
TABLE 76FRANCE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)113
TABLE 77FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)113
9.3.4SPAIN114
9.3.4.1Healthcare infrastructural improvements indicate favorable prospects for market growth in Spain114
TABLE 78SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)114
TABLE 79SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)114
TABLE 80SPAIN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)115
TABLE 81SPAIN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION)115
TABLE 82SPAIN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)115
TABLE 83SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)116
9.3.5UK116
9.3.5.1Frequent influenza outbreaks in the UK to boost the growth of the influenza diagnostics market116
TABLE 84UK: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)116
TABLE 85UK: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)117
TABLE 86UK: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)117
TABLE 87UK: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)117
TABLE 88UK: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)118
TABLE 89UK: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)118
9.3.6REST OF EUROPE118
TABLE 90ROE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)118
TABLE 91ROE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)119
TABLE 92ROE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)119
TABLE 93ROE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)119
TABLE 94ROE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)120
TABLE 95ROE: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)120
9.4ASIA PACIFIC120
FIGURE 26ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT121
TABLE 96ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)122
TABLE 97ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)122
TABLE 98ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)122
TABLE 99ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)123
TABLE 100ASIA PACIFIC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)123
TABLE 101ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)123
TABLE 102ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)124
9.4.1CHINA124
9.4.1.1Growing investments by government agencies to drive market growth in China124
 
TABLE 103CHINA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)124
TABLE 104CHINA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)125
TABLE 105CHINA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)125
TABLE 106CHINA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION)125
TABLE 107CHINA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)126
TABLE 108CHINA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)126
9.4.2JAPAN126
9.4.2.1Universal healthcare reimbursement policy to drive market growth in Japan126
TABLE 109JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)127
TABLE 110JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)127
TABLE 111JAPAN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)127
TABLE 112JAPAN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION)128
TABLE 113JAPAN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)128
TABLE 114JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)128
9.4.3INDIA129
9.4.3.1Increase in public and private investments in the country’s healthcare system will drive market growth129
TABLE 115INDIA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)129
TABLE 116INDIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)129
TABLE 117INDIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)130
TABLE 118INDIA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)130
TABLE 119INDIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)130
TABLE 120INDIA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)131
9.4.4REST OF ASIA PACIFIC131
TABLE 121ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)131
TABLE 122ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)132
TABLE 123ROAPAC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)132
TABLE 124ROAPAC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET,
BY TYPE, 2019–2026 (USD MILLION)132
TABLE 125ROAPAC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)133
TABLE 126ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)133
9.5LATIN AMERICA133
9.5.1RISING DISEASE PREVALENCE AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE THE LATAM MARKET133
TABLE 127LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)134
TABLE 128LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)134
TABLE 129LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)134
TABLE 130LATIN AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)135
TABLE 131LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE,
2019–2026 (USD MILLION)135
TABLE 132LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER,
2019–2026 (USD MILLION)135
9.6MIDDLE EAST & AFRICA136
9.6.1RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS WILL SUPPORT MARKET GROWTH136
TABLE 133MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)136
TABLE 134MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)136
TABLE 135MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)137
TABLE 136MIDDLE EAST & AFRICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)137
TABLE 137MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)137
TABLE 138MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)138
10COMPETITIVE LANDSCAPE139
10.1OVERVIEW139
10.2KEY PLAYER STRATEGIES/RIGHT TO WIN139
10.2.1OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET139
TABLE 139STRATEGIES ADOPTED BY KEY INFLUENZA DIAGNOSTIC PRODUCT MANUFACTURING COMPANIES139
10.3REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS140
FIGURE 27REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET140
 
10.4MARKET SHARE ANALYSIS141
FIGURE 28INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020)141
TABLE 140INFLUENZA DIAGNOSTICS MARKET: DEGREE OF COMPETITION142
10.5COMPANY EVALUATION QUADRANT143
10.5.1STARS143
10.5.2EMERGING LEADERS143
10.5.3PERVASIVE PLAYERS143
10.5.4PARTICIPANTS143
FIGURE 29INFLUENZA DIAGNOSTICS MARKET: COMPANY
EVALUATION QUADRANT, 2020144
10.6COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020)145
10.6.1PROGRESSIVE COMPANIES145
10.6.2STARTING BLOCKS145
10.6.3RESPONSIVE COMPANIES145
10.6.4DYNAMIC COMPANIES145
FIGURE 30INFLUENZA DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020146
10.7COMPETITIVE BENCHMARKING147
FIGURE 31PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET147
TABLE 141COMPANY PRODUCT FOOTPRINT147
TABLE 142COMPANY REGIONAL FOOTPRINT148
10.8COMPETITIVE SCENARIO148
10.8.1PRODUCT LAUNCHES & APPROVALS148
TABLE 143KEY PRODUCT LAUNCHES & APPROVALS148
10.8.2DEALS149
TABLE 144KEY DEALS149
11COMPANY PROFILES150
11.1KEY PLAYERS150
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1THERMO FISHER SCIENTIFIC, INC.150
TABLE 145THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW150
FIGURE 32THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)151
11.1.2BECTON, DICKINSON AND COMPANY154
TABLE 146BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW154
FIGURE 33BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)155
11.1.3F. HOFFMANN-LA ROCHE AG157
TABLE 147F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW157
FIGURE 34F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)158
11.1.4HOLOGIC, INC.160
TABLE 148HOLOGIC, INC.: BUSINESS OVERVIEW160
FIGURE 35HOLOGIC, INC.: COMPANY SNAPSHOT (2020)161
11.1.5ABBOTT LABORATORIES, INC.163
TABLE 149ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW163
FIGURE 36ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)164
11.1.6DANAHER CORPORATION167
TABLE 150DANAHER CORPORATION: BUSINESS OVERVIEW167
FIGURE 37DANAHER CORPORATION: COMPANY SNAPSHOT (2020)168
11.1.7QUIDEL CORPORATION170
TABLE 151QUIDEL CORPORATION: BUSINESS OVERVIEW170
FIGURE 38QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)171
11.1.8SIEMENS HEALTHINEERS174
TABLE 152SIEMENS HEALTHINEERS: BUSINESS OVERVIEW174
FIGURE 39SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)175
11.1.9BIOMÉRIEUX SA176
TABLE 153BIOMÉRIEUX SA: BUSINESS OVERVIEW176
FIGURE 40BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)177
11.1.10MERIDIAN BIOSCIENCE179
TABLE 154MERIDIAN BIOSCIENCE: BUSINESS OVERVIEW179
FIGURE 41MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2020)180
11.2OTHER PLAYERS181
11.2.1GENMARK DIAGNOSTICS, INC.181
11.2.2LUMINEX CORPORATION181
11.2.3TECAN TRADING AG182
11.2.4DIASORIN SA182
11.2.5ALTONA DIAGNOSTICS GMBH183
11.2.6SEKISUI DIAGNOSTICS183
11.2.7SA SCIENTIFIC, LTD.184
11.2.8CORIS BIOCONCEPT SPRL184
11.2.9ELITECH GROUP184
11.2.10MAST GROUP LTD.185
11.2.11GENOME DIAGNOSTICS PVT. LTD.185
11.2.12GERMAINE LABORATORIES, INC.185
11.2.13RESPONSE BIOMEDICAL CORP.186
11.2.14TAUNS LABORATORIES, INC.186
11.2.153B BLACKBIO BIOTECH INDIA LTD.186
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
12APPENDIX187
12.1INSIGHTS FROM INDUSTRY EXPERTS187
12.2DISCUSSION GUIDE188
12.3KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL190
12.4AVAILABLE CUSTOMIZATIONS192
12.5RELATED REPORTS192
12.6AUTHOR DETAILS193

お問合せフォーム